|
|
 Previous Article | Table of Contents | Next Article 
Sensitization of Hematopoietic Stem and Progenitor Cells to Trimetrexate Using Nucleoside Transport Inhibitors
James A. Allay,
H. Trent Spencer,
Sarah L. Wilkinson,
Judith A. Belt,
Raymond L. Blakley, and
Brian P. Sorrentino
From the Departments of Hematology and Oncology, Biochemistry, and Molecular Pharmacology, St Jude Children's Research Hospital, Memphis, TN.
Antifolates such as methotrexate (MTX) and trimetrexate (TMTX) are widely used in the treatment of cancer and nonmalignant disorders. Transient, yet sometimes severe myelosuppression is an important limitation to the use of these drugs. It has previously been shown that clonogenic myeloid progenitors and colony-forming units-spleen are resistant to antifolates, suggesting that myelotoxicity occurs late in hematopoietic development. The goal of this study was to define the mechanisms by which primitive hematopoietic cells resist the toxic effects of antifolate drugs. To test the hypothesis that myeloid progenitors may salvage extracellular nucleotide precursors to resist TMTX toxicity, a defined liquid culture system was developed to measure TMTX toxicity in expanding progenitor populations. These in vitro experiments showed that both human and murine progenitors can resist TMTX toxicity by importing thymidine and hypoxanthine from the serum. As predicted from these findings, several drugs that block thymidine transport sensitized progenitors to TMTX in vitro, although to differing degrees. These nucleoside transport inhibitors were used to test whether progenitors and hematopoietic stem cells (HSCs) could be sensitized to TMTX in vivo. Treatment of mice with TMTX and nitrobenzylmercaptopurineriboside phosphate (NBMPR-P), a potent transport inhibitor, caused significant depletions of clonogenic progenitors within the bone marrow (20-fold) and spleen (6-fold). Furthermore, NBMPR-P administration dramatically sensitized HSCs to TMTX, with dual-treated mice showing a greater than 90% reduction in bone marrow repopulating activity. These studies demonstrate that both myeloid progenitor cells and HSCs resist TMTX by using nucleotide salvage mechanisms and that these pathways can be pharmacologically blocked in vivo using nucleoside transport inhibitors. These results have important implications regarding the use of transport inhibitors for cancer therapy and for using variants of dihydrofolate reductase for in vivo selection of genetically modified HSCs.
Blood, Vol. 90 No. 9 (November 1), 1997:
pp. 3546-3554
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. L. Gori, K. Podetz-Pedersen, D. Swanson, A. D. Karlen, R. Gunther, N. V. Somia, and R. S. McIvor
Protection of Mice from Methotrexate Toxicity by ex Vivo Transduction Using Lentivirus Vectors Expressing Drug-Resistant Dihydrofolate Reductase
J. Pharmacol. Exp. Ther.,
September 1, 2007;
322(3):
989 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Neff, B. C. Beard, and H.-P. Kiem
Survival of the fittest: in vivo selection and stem cell gene therapy
Blood,
March 1, 2006;
107(5):
1751 - 1760.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. R. Belur, R. I. James, C. May, M. D. Diers, D. Swanson, R. Gunther, and R. S. McIvor
Methotrexate Preconditioning Allows Sufficient Engraftment to Confer Drug Resistance in Mice Transplanted with Marrow Expressing Drug-Resistant Dihydrofolate Reductase Activity
J. Pharmacol. Exp. Ther.,
August 1, 2005;
314(2):
668 - 674.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Richard, M. Weinreich, K.-H. Chang, J. Ieremia, M. M. Stevenson, and C. A. Blau
Modulating erythrocyte chimerism in a mouse model of pyruvate kinase deficiency
Blood,
June 15, 2004;
103(12):
4432 - 4439.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Persons, J. A. Allay, A. Bonifacino, T. Lu, B. Agricola, M. E. Metzger, R. E. Donahue, C. E. Dunbar, and B. P. Sorrentino
Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors
Blood,
February 1, 2004;
103(3):
796 - 803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Papadaki, H. D. Kritikos, C. Gemetzi, H. Koutala, J. C. W. Marsh, D. T. Boumpas, and G. D. Eliopoulos
Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect
Blood,
March 1, 2002;
99(5):
1610 - 1619.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Warlick, M. D. Diers, J. E. Wagner, and R. S. McIvor
In Vivo Selection of Antifolate-Resistant Transgenic Hematopoietic Stem Cells in a Murine Bone Marrow Transplant Model
J. Pharmacol. Exp. Ther.,
January 1, 2002;
300(1):
50 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. I. James, C. A. Warlick, M. D. Diers, R. Gunther, and R. S. McIvor
Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity
Blood,
August 15, 2000;
96(4):
1334 - 1341.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Patel, J. A. Allay, J. A. Belt, and B. P. Sorrentino
Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells
Blood,
April 1, 2000;
95(7):
2356 - 2363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Mackey, S. Y. M. Yao, K. M. Smith, E. Karpinski, S. A. Baldwin, C. E. Cass, and J. D. Young
Gemcitabine Transport in Xenopus Oocytes Expressing Recombinant Plasma Membrane Mammalian Nucleoside Transporters
J Natl Cancer Inst,
November 3, 1999;
91(21):
1876 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
